Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SEASPINE HOLDINGS CORPORATION

(SPNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

SeaSpine : to Participate in the Canaccord Genuity 41st Annual Growth Conference

07/28/2021 | 04:05pm EDT

CARLSBAD, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the Company will present at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11, 2021, beginning at 2:00 PM ET.

A live and archived webcast of the event will be available from the Investor Relations page of the Company's website at investor.seaspine.com.

About SeaSpine
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions, as well as a market leading surgical navigation system, to meet the varying combinations of products and enabling technologies that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in orthobiologic sciences, as well as spinal implants and software product development, allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.

Investor Relations Contact
Leigh Salvo
(415) 937-5402
ir@seaspine.com


Primary Logo

Source: SeaSpine Holdings Corporation

2021 GlobeNewswire, Inc., source Press Releases

All news about SEASPINE HOLDINGS CORPORATION
09/16SeaSpine to Host Analyst & Investor Event on September 30, 2021
GL
09/10ORTHOPEDIATRICS : SeaSpine Unit Enter Distribution Deal for 7D Flash Image Guida..
MT
09/09SEASPINE : OrthoPediatrics Announces Entry into a Distribution Agreement with Se..
AQ
09/08SEASPINE : Starts Limited Commercial Launch of Mariner Adult Deformity System
MT
09/07SEASPINE : Announces Initial Launch of Mariner Adult Deformity System
AQ
09/07SeaSpine Holdings Corporation Announces Initial Launch of Mariner Adult Defor..
CI
08/13SEASPINE : Commences Limited Commercial Sale of WaveForm A Interbody System
MT
08/12SEASPINE : Announces Limited Commercial Launch of the WaveForm® A (ALIF) 3D-Prin..
AQ
08/12SeaSpine Holdings Corporation Announces Limited Commercial Launch of the Wave..
CI
08/06SEASPINE : Files for Up to $250 Million Mixed-Securities Shelf
MT
More news
Analyst Recommendations on SEASPINE HOLDINGS CORPORATION
More recommendations
Financials (USD)
Sales 2021 202 M - -
Net income 2021 -34,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -14,9x
Yield 2021 -
Capitalization 582 M 582 M -
Capi. / Sales 2021 2,88x
Capi. / Sales 2022 2,56x
Nbr of Employees 421
Free-Float 84,7%
Chart SEASPINE HOLDINGS CORPORATION
Duration : Period :
SeaSpine Holdings Corporation Technical Analysis Chart | SPNE | US81255T1088 | MarketScreener
Technical analysis trends SEASPINE HOLDINGS CORPORATION
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 16,00 $
Average target price 28,61 $
Spread / Average Target 78,8%
EPS Revisions
Managers and Directors
Keith C. Valentine President, Chief Executive Officer & Director
John J. Bostjancic Chief Financial Officer, Treasurer & Senior VP
Kirtley C. Stephenson Non-Executive Chairman
Chris Shen VP-Information Technology & Customer Experience
Frank Vizesi Vice President-Clinical Affairs
Sector and Competitors